Publications

Pathogenic Interleukin-10 Receptor Alpha Variants in Humans — Balancing Natural Selection and Clinical Implications

Aschenbrenner D. et al, (2022), Journal of clinical immunology

COMBATdb: a database for the COVID-19 Multi-Omics Blood ATlas.

Wang D. et al, (2022), Nucleic acids res

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

POUWELS K. et al, (2022), Nature communications

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.

Wei J. et al, (2022), Nat med, 28, 1072 - 1082

FAS2FURIOUS: Moderate-throughput secreted expression of difficult recombinant proteins in Drosophila S2 cells

MIDWOOD KIM. et al, (2022), Frontiers in bioengineering and biotechnology, section synthetic biology

Venus: Elucidating the impact of amino acid variants on protein function beyond structure destabilisation

FERLA MP. et al, (2022), Journal of molecular biology

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.

Wei J. et al, (2022), Nat med

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Target 2035-update on the quest for a probe for every protein

Mueller S. et al, (2021), Rsc medicinal chemistry

Fragment Hotspot Mapping to Identify Selectivity-Determining Regions between Related Proteins

MARSDEN B. and VON DELFT F., (2021), Journal of chemical information and modeling

Symptoms and SARS-CoV-2 positivity in the general population in the UK.

Vihta K-D. et al, (2021), Clin infect dis

Symptoms and SARS-CoV-2 positivity in the general population in the UK.

Vihta K-D. et al, (2021), Clin infect dis

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population.

Wei J. et al, (2021), Nat commun, 12

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.

Wei J. et al, (2021), Nat microbiol, 6, 1140 - 1149

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.

Lumley SF. et al, (2021), Clin infect dis, 73, e699 - e709

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei J. et al, (2021)

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei J. et al, (2021)

An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status.

Lumley SF. et al, (2021), Clin infect dis

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.

Eyre DW. et al, (2021), Clin microbiol infect

Cookies on this website

Publications